文献速递肿瘤 PET/CT放射性药物与辐射防护

预靶向多模态成像用于结直肠癌模型图像引导切除的可行性研究

A pretargeted multimodal approach for image-guided resection in a xenograft model of colorectal cancer.
PubMed 文献 · EJNMMI Res · 2019-09-04

该临床前研究在结直肠癌皮下及腹腔荷瘤裸鼠模型中,评估了抗CEA×抗HSG双特异性抗体TF2联合双标记diHSG肽RDC018的预靶向策略用于多模态成像的可行性。结果显示预靶向的111In-RDC018在CEA阳性肿瘤中特异性摄取,SPECT/CT与近红外荧光成像均证实肿瘤优先聚集,并成功用于腹腔肿瘤的荧光引导切除。

要点

  • TF2预靶向联合111In-RDC018可实现CEA阳性结直肠癌的特异性多模态成像
  • 注射后2小时肿瘤摄取为21.9±4.5 %IA/g,24小时为10.0±4.7 %IA/g
  • 该策略支持术前SPECT/CT及术中近红外荧光引导肿瘤切除

核心结论

  • 在结直肠癌临床前异种移植模型中,预靶向多模态图像引导切除策略可行,支持术前SPECT/CT并可能促进术中荧光成像。

研究设计与样本

  • 采用荷皮下CEA表达LS174T人结肠肿瘤及CEA阴性对照肿瘤的裸鼠,注射TF2后16小时给予不同剂量的111In标记IMP-288或其荧光衍生物RDC018进行生物分布比较。
  • 在TF2预靶向荷瘤鼠中比较双标记人源化抗CEA IgG抗体[111In]In-DTPA-hMN-14-IRDye800CW直接靶向与111In-RDC018预靶向的生物分布。
  • 荷腹腔LS174T肿瘤小鼠接受近红外荧光图像引导切除,并联合切除前后microSPECT/CT成像。

主要发现

  • 111In-RDC018在预靶向CEA阳性肿瘤中显示特异性靶向,注射后2小时和24小时肿瘤摄取分别为21.9±4.5和10.0±4.7 %IA/g(mean±SD)。
  • 111In-RDC018的生物分布与111In-IMP288相似。
  • 荧光和microSPECT/CT图像均证实肿瘤优先聚集。
  • 尸检解剖时,使用TF2和111In-RDC018预靶向成功识别并切除了腹腔肿瘤。

临床怎么用

  • 该预靶向多模态策略可在临床前模型中实现术前SPECT/CT定位与术中近红外荧光引导切除的联合应用。

局限性

  • 研究仅为临床前异种移植模型,尚未在人体中验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Image-guided surgery may improve surgical outcome for colorectal cancer patients. Here, we evaluated the feasibility of a pretargeting strategy for multimodal imaging in colorectal cancer using an anti-carcinoembryonic antigen (CEA) x anti-histamine-succinyl-glycine (HSG) bispecific antibody (TF2) in conjunction with the dual-labeled diHSG peptide (RDC018), using both a fluorophore for near-infrared fluorescence imaging and a chelator for radiolabeling. METHODS: Nude mice with subcutaneous (s.c) CEA-expressing LS174T human colonic tumors and CEA-negative control tumors were injected with TF2. After 16 h, different doses of 111In-labeled IMP-288 (non-fluorescent) or its fluorescent derivative RDC018 were administered to compare biodistributions. MicroSPECT/CT and near-infrared fluorescence imaging were performed 2 and 24 h after injection. Next, the biodistribution of the dual-labeled humanized anti-CEA IgG antibody [111In]In-DTPA-hMN-14-IRDye800CW (direct targeting) was compared with the biodistribution of 111In-RDC018 in mice with TF2-pretargeted tumors, using fluorescence imaging and gamma counting. Lastly, mice with intraperitoneal LS174T tumors underwent near-infrared fluorescence image-guided resection combined with pre- and post-resection microSPECT/CT imaging. RESULTS: 111In-RDC018 showed specific tumor targeting in pretargeted CEA-positive tumors (21.9 ± 4.5 and 10.0 ± 4.7% injected activity per gram (mean ± SD %IA/g), at 2 and 24 hours post-injection (p.i.), respectively) and a biodistribution similar to 111In-IMP288. Both fluorescence and microSPECT/CT images confirmed preferential tumor accumulation. At post mortem dissection, intraperitoneal tumors were successfully identified and removed using pretargeting with TF2 and 111In-RDC018. CONCLUSION: A pretargeted approach for multimodal image-guided resection of colorectal cancer in a preclinical xenograft model is feasible, enables preoperative SPECT/CT, and might facilitate intraoperative fluorescence imaging.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Elekonawo FMK, Lütje S, Franssen GM, et al. A pretargeted multimodal approach for image-guided resection in a xenograft model of colorectal cancer. EJNMMI Res. 2019. PMID: 31485790. doi:10.1186/s13550-019-0551-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。